Project Grant 2451399
Award Date
3/1/25
Completion Date
2/28/26
Dollars Obligated
$305K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01606, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $295,000 to Theracea Pharma LC supports the development of innovative 18F-radiotracer kits for use in positron emission tomography (PET) imaging. The project aims to create advanced diagnostic tools to assist researchers and physicians, particularly in the field of oncology, by enabling more precise selection and assessment of cancer therapies, including immunotherapy. The...
The National Science Foundation (NSF) awarded a $275,000 SBIR Phase I grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Om Therapeutics Inc. in La Jolla, CA. The goal of this project is to enable the discovery of new medicines at an unprecedented rate by empowering researchers to launch drug discovery programs quickly and cost-effectively. The innovation involves the ability to screen billions of unique small molecules against the entire human proteome in a...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Foragr Medicines, Inc. will support the development of a high-throughput platform for small molecule, in-cell targeting of undruggable proteins via their mRNAs. The project aims to create an efficient and cost-effective approach for developing therapeutics for previously undruggable diseases, including hard-to-treat neurodegenerative diseases and aggressive cancers....
The National Science Foundation (NSF) awarded a $274,966 Project Grant to Remedium Bio Inc., a for-profit organization, under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant supports the development of an adjustable gene therapy platform technology that will enable the use of genetic therapeutics beyond rare diseases, tackling large unmet clinical needs such as diabetes, osteoarthritis, and autoimmune diseases. The project aims to develop a dose-adjustable...
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000.00 to Eugit Therapeutics, Inc. to develop a novel platform for identifying agents that can specifically accumulate in diseased tissues. The primary goal is to create a proof of concept demonstrating the ability to uncover agents capable of targeted delivery to the gastrointestinal tract, with a focus on improving treatments for...
The National Science Foundation (NSF) awarded a $303,864 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics Inc., a for-profit organization located in Ladera Ranch, CA. The grant, awarded on April 1, 2025, aims to develop a platform for discovering and rapidly developing disruptive drug candidates by determining the mechanisms driving diseases at the molecular network level. The project objectives include demonstrating that...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Islex Therapeutics, LLC to develop antibody therapeutics for the treatment of stage 3 type-1 diabetes (T1D). The key objectives are to demonstrate the efficacy and safety of beta-cell restorative therapies in preclinical studies, which could lead to new treatment options for millions of patients with severe beta-cell loss. The research initiative...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 was granted to Absco Therapeutics, Inc. (Abscotx) on April 15, 2025 to develop an image-guided intratumoral delivery system for biologic cancer immunotherapies. The project aims to improve localized retention and controlled release of biologic drugs within solid tumors, addressing limitations of current systemic administration methods that suffer from rapid drug...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Genexgen Inc., a small disadvantaged business, is providing $274,763 to develop an mRNA-based tolerogenic vaccine to address immune response challenges in viral-based gene therapies. The proposed solution aims to train the immune system to ignore antigens expressed in gene therapy treatments, enabling higher and more persistent therapeutic protein expression. This could...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Junipero Therapeutics, Inc. aims to develop an innovative gene therapy platform using epigenome editing techniques. The project seeks to overcome limitations of current gene therapy methods by leveraging oligonucleotide-conjugates to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible manner. The research plan...